Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Publication year range
1.
AIDS Res Hum Retroviruses ; 23(1): 175-80, 2007 Jan.
Article in English | MEDLINE | ID: mdl-17263648

ABSTRACT

In 2002, an HIV surveillance study was performed among more than 5500 individuals representing the general population of urban and rural districts in Burundi. In this report, we genetically characterized a subset of the HIV-1-positive samples identified during this survey, including all the HIV-positive samples from Bujumbura, the capital city, and samples from one semiurban and one rural district. One hundred and nineteen samples were genetically characterized in the V3-V5 region of the env gene and/or in the protease and reverse transcriptase region of the pol gene. Phylogenetic analysis of 101 env/pol sequences revealed that the HIV-1 epidemic in Burundi was driven by subtype C (81.2%), followed by subtype A (7.9 %) and polC/envA recombinants (5.9%). One major mutation associated with resistance to antiretroviral drugs (ARVs) in the pol gene, as defined by the International AIDS Society Resistance Testing-USA panel, was observed in one individual, but many minor resistance-associated mutations were also present in the majority of the samples.


Subject(s)
Anti-Retroviral Agents/therapeutic use , Drug Resistance, Viral/genetics , Genetic Variation , HIV Infections/virology , HIV-1/genetics , Base Sequence , Burundi/epidemiology , Gene Products, env , Gene Products, pol , Genes, env , Genes, pol , HIV Infections/drug therapy , HIV Infections/epidemiology , HIV-1/classification , HIV-1/drug effects , Humans , Molecular Sequence Data , Phylogeny , Recombination, Genetic
2.
Trop Med Int Health ; 9(6): 673-9, 2004 Jun.
Article in French | MEDLINE | ID: mdl-15189457

ABSTRACT

Faced with the problem of resistance to chloroquine and sulfadoxine-pyrimethamine, the Ministry of Public Health of Burundi decided to study the efficacy of two artemisinin-based combinations, the fixed combination of artemether-lumefantrine and the combination of amodiaquine + artesunate. The efficacy of these combinations for the treatment of uncomplicated falciparum malaria was studied in two sites representative of the country, in Kigobe neighbourhood of Bujumbura, the capital city, and in Buhiga, a rural area. The study followed the standardized WHO protocol from October 2001 to November 2002. A total of 295 children under 5 years were included; 153 children were treated with artesunate and amodiaquine (77 at Buhiga and 76 at Kigobe), and 142 children with the combination of artemether-lumefantrine (64 at Buhiga and 78 at Kigobe). Among the 295 children, 290 were followed up to 14 days. In the group of 149 children treated with artesunate and amodiaquine, 142 (95.3%, 95% CI: 91.9-98.7%) presented with adequate clinical and parasitological response, five (3.3%) with late parasitological failure, one (0.7%) with late clinical failure and one (0.7%) with early treatment failure. Among the 141 children treated with artemether-lumefantrine, 140 (99.3%, 95% CI: 97.9-100%) presented with adequate clinical and parasitological response and one (0.7%) with late parasitological failure at Buhiga. Side-effects were comparable in both groups except for the vomiting. Vomiting was more frequent in the artesunate + amodiaquine on D1 and D2. Both treatments decreased the gametocyte carriage but without getting full clearance in all the patients. During a consensus workshop, the Ministry of Public Health agreed on the combination of artesunate and amodiaquine as the first line drug for the treatment of uncomplicated falciparum malaria in Burundi including epidemic outbreak.


Subject(s)
Antimalarials/therapeutic use , Artemisinins/therapeutic use , Malaria, Falciparum/drug therapy , Amodiaquine/adverse effects , Amodiaquine/therapeutic use , Antimalarials/adverse effects , Artemether , Artemisinins/adverse effects , Artesunate , Burundi/epidemiology , Child, Preschool , Drug Resistance , Drug Therapy, Combination , Ethanolamines/adverse effects , Ethanolamines/therapeutic use , Female , Fluorenes/adverse effects , Fluorenes/therapeutic use , Humans , Lumefantrine , Malaria, Falciparum/epidemiology , Male , Rural Health , Sesquiterpenes/adverse effects , Sesquiterpenes/therapeutic use , Treatment Failure , Urban Health , Vomiting/chemically induced
SELECTION OF CITATIONS
SEARCH DETAIL
...